Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 3/20 | 0.53 |
| ▸ | KDM4B | O94953 | 3/20 | 0.53 |
| ▸ | KDM5C | P41229 | 3/20 | 0.53 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.53 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL334691 | 0.74 | PARP1 (0.55) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL5139409 | 0.73 | KDM4A (0.44) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL496650 | 0.71 | — | — | |
| SCHEMBL31082754 | 0.71 | KDM4A (0.42) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL1886926 | 0.69 | KDM4C (1.00) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL6837342 | 0.68 | PARP1 (0.46) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL21808624 | 0.68 | PARP1 (0.46) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL19153800 | 0.68 | PARP1 (0.50) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL30979186 | 0.68 | PARP1 (0.46) | KDM4AKDM4BKDM5CKDM5BKDM4C | |
| SCHEMBL26155897 | 0.68 | ALDH1A1 (0.50) | KDM4AKDM4BKDM5CKDM5BKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3854799-B1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | SHANGHAI DE NOVO PHARMATECH CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| EP-3854799-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020057546-A1 | CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION | 上海迪诺医药科技有限公司 | 2020-03-26 | — | — | WO | disclosed |
| WO-2015155306-A1 | NEW TRPA1 ANTAGONISTS | ALMIRALL, S.A. (ES) | 2015-10-15 | — | — | WO | disclosed |
| US-7332498-B2 | Modulation of KSP kinesin activity with heterocyclic-fused pyrimidinone derivatives | CYTOKINETICS, INC. (US) | 2008-02-19 | — | — | US | disclosed |
| EP-1513820-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-20060111374-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-7038048-B2 | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use | CYTOKINETICS, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1513820-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116438-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2004-06-17 | — | — | US | disclosed |
| WO-2003103575-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111374-A1 | Compounds, compositions, and methods | ALPP, MKI67, PCNA | KDM4A 1300/4885KDM4B 1258/4885KDM5C 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.